Primary plasma cell leukemia

Plasma cells normally live mainly in marrow and make antibodies. In plasma cell leukemia, malignant plasma cells circulate in blood as well as involving marrow and sometimes other organs.

“Primary” means the leukemic presentation is present from the initial diagnosis. “Secondary” plasma cell leukemia develops from previously diagnosed myeloma and has a different treatment history. Specialist review of blood, marrow and genetic findings is important.

Acquired genetic changes in the plasma-cell clone contribute to aggressive growth and the ability to circulate outside marrow. The cause in an individual is usually unknown.

This is not a contagious disease. It shares some biology with multiple myeloma but should not be treated as ordinary lower-risk myeloma or as a leukemia of immature lymphocytes.

Anemia and low platelets can cause marked fatigue, breathlessness or bleeding. Kidney impairment, high calcium, infections and enlarged organs may occur, while bone disease can also be present.

The pace of illness and high circulating cell burden can create urgent treatment needs, including monitoring for tumor lysis and support for kidney function, blood counts and infection.

Treatment commonly uses combinations drawn from modern myeloma therapy, including a proteasome inhibitor, an immunomodulatory medicine, a steroid and often an anti-CD38 antibody. Fitness, organ function and trial availability guide the plan.

Eligible patients may proceed to high-dose chemotherapy and autologous stem cell rescue after initial treatment. Tandem approaches, in which a second transplant follows the first, have been studied. These may involve two autologous transplants or an autologous followed by an allogeneic transplant.

No randomized evidence establishes one transplant sequence for every patient with primary plasma cell leukemia. Allogeneic treatment may reduce some relapse risks but adds substantial treatment-related risk. Maintenance or further systemic therapy is often part of planning because relapse remains a concern.

Treatment can move quickly from initial disease control to cell collection and transplant assessment. Transfusions, infection prevention and management of kidney or metabolic problems may be needed throughout.

A proposed tandem plan means more than one period of intensive treatment and recovery. The team should explain the purpose and cell source of each procedure, the evidence supporting it and the alternatives if the response or health situation changes.

An autologous transplant uses the person’s own collected blood-forming cells. It does not require an unrelated registry match.

A donor is relevant if an allogeneic transplant is selected as part of an individualized strategy. Relatives, unrelated volunteers or alternative grafts may be considered. Donor registration supports that option but should not imply that a donor transplant is proven superior for every person with this rare disease.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?